Collaboration focuses on launching an AI-powered biomarker prediction panel targeting actionable biomarkers to revolutionize lung cancer diagnostics and enable commercialization of a diagnostic panel.

根据 Insight 数据库「中国上市策略 & 时长预测」模块， 2025 年预计将有 40 款抗肿瘤新药首次在国内获批上市。本文将节选其中 15 个潜在重磅抗肿瘤新药信息进行分享，仅供读者参阅（以下排名不分先后）。强生：塔奎妥单抗 CD3 × ...

Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...

Topline data on a combo including Pfizer’s kinase inhibitor Braftovi point to improved progression-free survival and pave the ...

同时，不少已经被CDE纳入突破性治疗品种的新药也陆续迈入上市申请阶段，有望在2025年在中国获批上市。本文将盘点22款*有望在2025年获NMPA批准上市的“突破性”新药，看看这些突破性疗法有望造福哪些疾病患者。

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

(Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

BH-30643 is an OMNI-EGFR inhibitor that targets classical, atypical, and compound EGFR mutations and acquired resistance mutations in HER2.

近日，乐普生物宣布，与海外生物制药公司ArriVent BioPharma, Inc.就针对消化道癌的潜在同类最佳抗体偶联药物MRG007达成全球独家许可协议。2025年国产ADC出海再添一员。 根据协议，乐普生物授予ArriVent在大中华区（包括中国内地、中国香港、中国澳门和中国台湾）以外地区开发、制造和商业化MRG007的全球独家许可。 乐普生物将获得总计4700万美元的一次性首付款和近期里 ...

Food - Allergen - Tree nut Distribution:NationalOnline See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA) ...

Activation of EGF receptor and HER2 is an important factor for initiation and progression of malignancies, including breast cancer where the status of HER2 is an essential step in the diagnostic ...